CASE STUDY Strong Site Selection Leads to Success PRA Screens 5 Months Ahead of ScheduleStrong Site Selection Leads to Success PRA Screens 5 Months Ahead of Schedule Regions North America Western Europe Central Europe Eastern Europe Asia Pacific STUDY DESCRIPTION A randomized, double-blind, placebo-controlled Phase III study of Study Drug versus placebo for patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatments PRA was selected to conduct a global Phase III gastrointestinal stromal tumors (GIST) study for a top 20 large pharmaceutical client. Situation Study Duration 33 months No. of Clinical Sites 85 Treatment Period 6 months Patient Population 170 Primary Endpoint Progression PRA Services Full service Indication GIST Drug Class M

Join for free to read